Carregant...
Genome-Scale Metabolic Modeling of Glioblastoma Reveals Promising Targets for Drug Development
Glioblastoma (GBM) is an aggressive type of brain cancer with a poor prognosis for affected patients. The current line of treatment only gives the patients a survival time of on average 15 months. In this work, we use genome-scale metabolic models (GEMs) together with other systems biology tools to...
Guardat en:
| Publicat a: | Front Genet |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7181968/ https://ncbi.nlm.nih.gov/pubmed/32362913 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fgene.2020.00381 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|